SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - May 18, 2012) -
NicOx's Ordinary Shareholder Meeting
May 18, 2012. Sophia Antipolis, France. www.nicox.com
NicOx S.A. (EURONEXT: COX) (
The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, are sent to shareholders upon written request. These documents will also be made available to shareholders at the headquarters and on the website of the Company (www.nicox.com).
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international late-stage development and commercial Ophthalmology Company based around therapeutics, diagnostics and devices. As of March 2012, NicOx holds an 11.8% stake in the UK-based ophthalmology company Altacor, with an option to acquire the remaining shares, as the first step of a transformation into a late-stage development and commercial ophthalmic Company.
NicOx is also developing an internal portfolio of New Molecular Entities (NMEs) through the application of its proprietary nitric oxide-donating R&D platform. The Company's pipeline includes several nitric oxide-donating NMEs for the potential treatment of ophthalmological, inflammatory and cardio-metabolic diseases, which are in development internally and with partners, who include Bausch + Lomb, Merck (known as MSD outside the United States and Canada) and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps).
Risks factors which are likely to have a material effect on NicOx's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2010 » filed with the French Autorité des Marchés Financiers (AMF) on February 29, 2012 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).
NicOx's Ordinary Shareholder Meeting on June 6, 2012: http://hugin.info/143509/R/1613226/513706.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE